AbbVie Declares $1.73 Quarterly Dividend, Reinforcing Long-Term Capital Allocation Strategy

AbbVie declares quarterly payout as part of long-term capital plan

Dividend Policy Anchors Capital Allocation Strategy

AbbVie announces a quarterly cash dividend of $1.73 per share, payable May 15, 2026 to shareholders of record at the close of business on April 15, 2026. The company frames the declaration as part of its broader capital-allocation priorities and says the move complements disclosures tied to its full-year and fourth-quarter 2025 results.

The company says it has raised its dividend more than 330% since AbbVie’s 2013 inception and highlights membership in the S&P Dividend Aristocrats Index, which tracks firms that have increased payouts for at least 25 consecutive years. AbbVie presents the dividend decision as evidence of a sustained focus on returning cash to shareholders while maintaining investment in its business.

AbbVie positions the payout as aligned with its mission to fund long-term growth across key therapeutic areas. Executives emphasise that continuing dividend increases and other returns of capital sit alongside ongoing operational priorities, including integration of Allergan Aesthetics initiatives and the delivery of medicines in immunology, neuroscience and oncology.

Allergan Aesthetics and pipeline priorities

AbbVie reiterates its commitment to discovering and delivering innovative medicines and highlights product and services within the Allergan Aesthetics portfolio as part of its growth mix. The company stresses that aesthetic offerings, together with therapeutic pipelines in immunology, neuroscience and oncology, underpin its strategy to diversify revenue and support long-term shareholder returns.

Documentation and investor access

AbbVie points investors and the media to its website and PR Newswire for the full press release, detailed fourth-quarter and full-year 2025 financial results, regulatory filings and investor presentations. Media inquiries are directed to the company’s communications contact and investor queries to its investor relations team, with materials posted for confirmation and archival access.